Article
Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention.
Heart (British Cardiac Society) - 1 Sept 2012
Park Kyung Woo, Kang Jeehoon, Park Jin Joo, Yang Han-Mo, Lee Hae-Young, Kang Hyun-Jae, Koo Bon-Kwon, Oh Byung-Hee, Park Young-Bae, Kim Hyo-Soo
Abstract excerpt
OBJECTIVE: To test the effect of a loss-of-function variation of the cytochrome P450 (CYP) 3A5 on drug-drug interaction between amlodipine and clopidogrel. Amlodipine is a well-known inhibitor of CYP 3A4, an isoenzyme of CYP3A that activates clopidogrel. However, controversy exists regarding whether amlodipine adversely affects clopidogrel response and clinical outcome after percutaneous coronary intervention...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
